Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 7:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 2,005 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Discrete Clear all

Conditions: Actinic Keratosis, Imipramine, Photodynamic Therapy
Interventions: Imipramine, Control Vehicle; Drug · Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Dayton, Ohio

Conditions: Breast Carcinoma
Interventions: Counseling, Written materials; Behavioral
Lead sponsor: American Scitech International; Other
Eligibility: 25 Years to 85 Years · Female only
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Englishtown, New Jersey

Conditions: Mydriasis
Interventions: Tropicamide/Phenylephrine ophthalmic solution (TR/PE), Placebo; Drug
Lead sponsor: Eyenovia Inc.; Industry
Eligibility: Not listed
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Austin, Texas • San Antonio, Texas

Conditions: Spinal Cord Injuries (SCI), Orthostatic Hypotension, Dysautonomic, Cardiovascular, Transcutaneous Spinal Stimulation
Interventions: spinal cord transcutaneous stimulation, Ice testing; Device · Procedure
Lead sponsor: Kessler Foundation; Other
Eligibility: 18 Years to 75 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: West Orange, New Jersey

Conditions: Breast Cancer, Cardiotoxicity, Cardiovascular Diseases
Interventions: High Intensity Interval Exercise, Moderate Intensity Walking; Behavioral
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Heart Failure
Interventions: CXL-1020, Placebo for CXL-1020 Cohort 1, Placebo for CXL-1020 Cohort 2, CXL-1020 Dose for Echo Cohort A, CXL-1020 Doses for Echo Cohort B; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Tustin, California

Conditions: Spinal Cord Injuries
Interventions: Acute Intermittent Hypoxia (AIH), Acute Intermittent Hypercapnic-Hypoxia (AIHH), Sham AIH; Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 70 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Asthma
Interventions: Dupilumab, Placebo; Drug · Other
Lead sponsor: Sally E. Wenzel MD; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Adult T-Cell Leukemia/Lymphoma, Aplastic Anemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Essential Thrombocythemia, Hematopoietic and Lymphatic System Neoplasm, Hodgkin Lymphoma, Multiple Myeloma, Myelodysplastic Syndrome, Myelofibrosis, Myeloid Neoplasm, Non-Hodgkin Lymphoma, Polycythemia Vera, Small Lymphocytic Lymphoma
Interventions: Fludarabine, Total-Body Irradiation, Donor Lymphocyte Infusion, Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil, Hematopoietic Cell Transplantation, Melphalan, Bone Marrow Aspiration and Biopsy, Diagnostic Imaging, Biospecimen Collection; Drug · Radiation · Procedure
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2032
U.S. locations: 1
States / cities: Philadephia, Pennsylvania

Conditions: Sepsis, Septic Shock, Acute Kidney Injury, Metformin
Interventions: Metformin low dose, Metformin high dose, Placebo; Drug
Lead sponsor: Hernando Gomez; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Psoriasis
Interventions: Fluphenazine, Placebo; Drug
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: Boston, Massachusetts • New Brunswick, New Jersey

Conditions: Chronic Pain, Temporomandibular Joint Disorders, Temporomandibular Joint Pain
Interventions: Not listed
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Traumatic Brain Injury
Interventions: Not listed
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 7
States / cities: San Francisco, California • Miami, Florida • Boston, Massachusetts + 4 more

Conditions: Depression
Interventions: Omega-3 Supplementation, Psychoeducational Psychotherapy (PEP), Placebo; Drug · Behavioral · Other
Lead sponsor: L. Eugene Arnold; Other
Eligibility: 7 Years to 14 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Lung Cancer
Interventions: Boost Stereotactic Body Radiation Therapy; Radiation
Lead sponsor: Ronald McGarry; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2018
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Parkinsonian Syndromes
Interventions: 123 I - ALTROPANE®; Drug
Lead sponsor: Alseres Pharmaceuticals, Inc; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Hopkinton, Massachusetts

Conditions: Asthma, Lung Diseases
Interventions: Asthma: It's a Family Affair!, Asthma and Stress Comparator; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 11 Years to 14 Years
Enrollment: 392 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Myelodysplastic Syndromes
Interventions: Dasatinib; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Drug Abuse
Interventions: Intravenous placebo, Intranasal placebo, Intravenous racemic ketamine, Esketamine 112 mg, Esketamine 84 mg; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Healthy
Interventions: Rilpivirine, Rilpivirine Long-acting Parenteral Formulation; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Tempe, Arizona • Lincoln, Nebraska

Conditions: Prostate Adenocarcinoma, Prostate Carcinoma
Interventions: Magnetic Resonance Imaging; Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Neuropathic Back Pain, Spinal Cord Injury
Interventions: Botulinum Toxin A, Placebo; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 80 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Head and Neck Cancer, Cancer of the Pharynx, Cancer of the Larynx, Nose Neoplasms, Paranasal Sinus Neoplasms, Cancer of the Oral Cavity
Interventions: Cetuximab, Hydroxyurea, Fluorouracil, radiotherapy; Drug · Procedure
Lead sponsor: Johnny Kao; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Decreasing Destructive Behavior, Increasing Functional Communicative Behavior
Interventions: Traditional Schedule Thinning, PIA-Informed Schedule Thinning, PIA-Informed Schedule Thinning with Competing Stimuli; Behavioral
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 3 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 2
States / cities: New Brunswick, New Jersey • Somerset, New Jersey

Search by objective public record fields.

The Effect of Topical Imipramine on Photodynamic Therapy-Mediated Immunosuppression on Forearms or Face on US Veterans

Determining Quality of Life in Breast Cancer Patient After Completing Radiation,Chemotherapy,Surgery or Combination

Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation

Cardiovascular Function and Response to Stimulation Within the First Year After Spinal Cord Injury

The Effects of Two Exercise Interventions on Breast Cancer Patients Undergoing Cardiotoxic Chemotherapies

Safety and Hemodynamic Effects and Pharmacokinetics of CXL-1020 in Patients With Stable Heart Failure

BioFLO for Respiratory Recovery in SCI

Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma

Two Step Haplo With Radiation Conditioning

Safety and Feasibility of Metformin for Sepsis Induced AKI

Fluphenazine Hydrochloride for Psoriasis

Brain Connectivity Patterns in Chronic Temporomandibular Joint Disorders

Spreading Depolarizations in Traumatic Brain Injury

Omega-3 and Therapy Study for Depression

Stereotactic Body Radiation Therapy in Stage II/III Non Small Cell Lung Cancer

Two Separate But Identical Studies Evaluating the Safety and Efficacy of ALTROPANE® in the Use of SPECT Imaging for Upper Extremity Tremor

Family Approach to Managing Asthma in Early Teens

Study of Oral Dasatinib in Subjects With Myelodysplastic Syndrome (MDS) and Excess Marrow Blasts

Crossover Study to Evaluate the Abuse Potential of Intranasal Esketamine Compared to Racemic Intravenous Ketamine in Nondependent, Recreational Drug Users

A Study to Investigate the Effect of Different Particle Sizes on the Single-dose Pharmacokinetics of Rilpivirine After Intramuscular Injection of a Long-acting Nanosuspension in Healthy Participants

Novel Synthetic T2W MR Imaging and Spin Parameter Mapping Techniques for Screening Prostate Cancer

Injecting Botulinum Toxin A Underneath the Skin to Treat Spinal Cord Pain in Patients With Spinal Cord Injury

Fluorouracil, Hydroxyurea, Cetuximab and Twice-daily Intensity Radiation Therapy for Advanced Head and Neck Cancer

Motivational Refinements for Facilitating Reinforcement Schedule Thinning